cost‑effectiveness
Evaluating the cost‑effectiveness of oral semaglutide (OASIS trials) versus injectable GLP‑1 therapies for adult obesity management - story-based
Oral semaglutide delivers weight-loss results similar to injectable GLP-1 drugs while lowering pharmacy and administration expenses by roughly 30 percent, making it a cost-effective choice for adult obesity treatment. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional
